Reserpine inhibits amphetamine action in ventral midbrain culture

Molecular Pharmacology

Volumn 49, Issue 2, 1996, Pages 338-342

  Sulzer, David ^a,b   Remy, Carl St ^a,b   Rayport, Stephen ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; RESERPINE;

ANIMAL TISSUE; ARTICLE; CATECHOLAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DRUG MECHANISM; MESENCEPHALON; NONHUMAN; PRIORITY JOURNAL; SYNAPSE VESICLE;

AMPHETAMINE; ANIMALS; CELLS, CULTURED; CYTOSOL; DOPAMINE; KINETICS; NEURONS; RESERPINE; SYNAPTIC VESICLES; TIME FACTORS; VENTRAL TEGMENTAL AREA;

EID: 9044248944     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Koob, G. F., and F. E. Bloom. Cellular and molecular mechanisms of drug dependence. Science (Washington D. C.) 242:715-723 (1988).
2. Chien, J. B., E. A. Wallingford, and A. G. Ewing. Estimation of free dopamine in the cytoplasm of the giant dopamine cell of Planorbis corneus by voltammetry and capillary electrophoresis. J. Neurochem. 54:633-638 (1990)
3. Slotkin, T. A., T. R. Anderson, F. J. Seidler, and C. Lau. Inhibition of epinephrine and metaraminol uptake into adrenal medullary vesicles by aralkylamines and alkylamines. Biochem. Pharmacol. 24:1413-1419 (1975).
4. Knepper, S. M., G. L Grunewald, and C. O. Rutledge. Inhibition of norepinephrine transport into synaptic vesicles by amphetamine analogs. J. Pharmacol. Exp. Ther. 247:487-494 (1988).
5. Schuldiner, S., S. Steiner-Mordoch, R. Yelin, S. C Wall, and G. Rudnick. Amphetamine derivatives interact with both plasma membrane and secretory vesicle biogenic amine transporters. Mol. Pharmacol. 44:1227-1231 (1993).
6. Sulzer, D., and S. Rayport. Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: a mechanism of action. Neuron 5:797-808 (1990).
7. Peter, D , J. Jiminez, Y. Liu, J. Kim, and R. Edwards. The chromaffin granule and synaptic vesicle amine transporters differ in substrate recognition and sensitivity to inhibitors. J. Biol. Chem. 269:7231-7237 (1994).
8. Floor, E, P S. Leventhal, Y. Wang, L. Meng, and W. Chen. Dynamic storage of dopamine in rat brain synaptic vesicles in vitro. J. Neurochem. 64:689-699 (1995).
9. Burn, J. H., and M. J Rand. The action of sympathomimetic amines in animals treated with reserpine. J. Physiol. (Lond.) 144:314-336 (1958).
10. Rayport, S., D. Sulzer, W.-X. Shi, S. Sawasdikosol, J Monaco, D. Batson, and G. Rajendran. Identified postnatal mesolimbic dopamine neurons in cell culture: morphology and electrophysiology. J. Neurosci. 12:4264-4280 (1992).
11. Bagchi, S. P., T. M Smith, and P. Bagchi. Divergent reserpine effects on amfonelic acid and amphetamine stimulation of synaptosomal dopamine formation from phenylalanine. Biochem. Pharmacol. 29:2957-2962 (1980).
12. 3H]Dopamine release by d-amphetamine from striatal synaptosomes of reserpinized rats. Biochem. Pharmacol. 31:1969-1874 (1982).
13. Shalaby, I. A, C. Kotake, P. C. Hoffmann, and A. Heller. Release of dopamine from coaggregate cultures of mesencephalic tegmentum and corpus striatum. J. Neurosci. 3:1565-1571 (1983).
14. Niddam, S., S. Arbilla, T. Scatton, T. Dennis, and S. Z. Langer. Amphetamine induced release of endogenous dopamine in vitro is not reduced following pretreatment with reserpine. Naunyn-Schmiedebergs Arch. Pharmacol. 329:123-127 (1985).
15. Arbuthnott, G. W., I S. Fairbrother, and S. P. Butcher. Dopamine release and metabolism in the rat striatum: an analysis by 'in vivo' brain microdialysis. Pharmacol. Ther. 48:281-293 (1990).
16. Callaway, C. W., R. Kuczenski, and D. S. Segal. Reserpine enhances amphetamine stereotypes without increasing amphetamine-induced changes in striatal dialysate dopamine. Brain Res. 505:83-90 (1989).
17. Butcher, S. P., I. S. Fairbrother, J. S. Kelly, and G. W. Arbuthnott. Amphetamine-induced dopamine release in the rat striatum: an in vivo microdialysis study. J. Neurochem. 50:346-355 (1988).
18. Parker, E. M., and L. X. Cubeddu. Effects of d-amphetamine and dopamine synthesis inhibitors on dopamine and acetylcholine neurotransmission in the striatum. J Pharmacol. Exp. Ther. 237:179-203 (1986).
19. Parker, E. M., and L. X Cubeddu. Comparative effects of amphetamine, phenylethylamine and related drugs on dopamine efflux, dopamine uptake and mazindol binding. J. Pharmacol. Exp. Ther. 245:199-210 (1988).
20. Sabol, K. E., J. B. Richards, C. S. Brent, and L. S. Seiden. Reserpine attenuates high and low dose amphetamine-induced dopamine release in vivo. Soc. Neurosci. Abstr. 19:740 (1993).
21. Heeringa, M. J., and E. D. Abercrombie. Biochemistry of somatodendritic dopamine release in substantia nigra: an in vivo comparison with striatal dopamine release. J. Neurochem., in press.
22. Florin, S. M., R. Kuczenski, and D. S. Segal. Effects of reserpine on extracellular caudate dopamine and hippocampus norepinephrine responses to amphetamine and cocaine: mechanistic and behavioral considerations. J. Pharmacol. Exp. Ther. 274:231-241 (1995).
23. Pasinetti, G. M., D. G. Morgan, S. A Johnson, S. L Millar, and C. E. Finch. Tyrosine hydroxylase mRNA concentration in midbrain dopaminergic neurons differentially regulated by reserpine. J. Neurochem. 55:1793-1799 (1990).
24. Pifl, C., H. Drobny, H. Reither, O. Hornykiewicz, and E. A. Singer. Mechanism of the dopamine-releasing actions of amphetamine and cocaine: plasmalemmal dopamine transporter versus vesicular monoamine transporter. Mol. Pharmacol. 47:368-373 (1995).
25. Eshelman, A. J., R. A. Henningsen, K. A. Neve, and A. Janowsky. Release of dopamine via the human transporter. Mol. Pharmacol. 45:312-316 (1994).
26. Wall, S. C., H. Gu, and G. Rudnick. Biogenic amine flux mediated by cloned transporters stably expressed in cultured cells lines: amphetamine specificity for inhibition and efflux Mol. Pharmacol. 47:544-550 (1995).
27. Cammack, J. N., S. V. Rakhilin, and E. A. Schwartz. A γ-aminobutyric acid transporter operates asymmetrically and with variable stochiometry. Neuron 13:949-960 (1994).
28. Sulzer, D., T. K. Chen, Y. Y. Lau, H. Kristensen, S. Rayport, and A. Ewing. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J. Neurosci. 15:4102-4108 (1995).
29. 3H]amphetamine with rat brain synaptosomes. II. Active transport. J. Pharmacol. Exp Ther. 257:830-835 (1991).
30. Fischer, J. F., and A. K. Cho. Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model. J. Pharmacol. Exp. Ther. 208:203-209 (1979).
31. Kuhr, W. G., A. G. Ewing, and E. M. Wightman. Amphetamine attenuates the stimulated release of dopamine in vivo. J. Pharmacol. Exp. Ther. 232:388-394 (1985).
32. Fitzgerald, J. L., and J. J. Reid. Interactions of methylenedioxymethamphetamine with monoamine transmitter release mechanisms in rat brain slices. Naunyn-Schmiedebergs Arch. Pharmacol. 347:313-323 (1993).
33. Patrick, R. L., A. L. Berkowitz, and A. C Regenstein. Effects of in vivo amphetamine administration on dopamine synthesis regulation in rat brain striatal synaptosomes. J. Pharmacol. Exp. Ther. 217:686-691 (1981).
34. 3H-norepinephrine released from the adrenergic neuron. J. Pharmacol. Exp. Ther. 178:464-473 (1971).
35. 3H]dopamine from isolated corpus striatum by amphetamine, fenfluramine, and unlabeled dopamine. Biochem. Pharmacol. 31:983-992 (1982).
36. Kahsker, A., J. C. Waymire, and C. O. Rutledge. Effects of 6-hydroxydopamine and reserpine on amphetamine-induced release of norepinephrine in rat cerebral cortex. J. Pharmacol. Exp. Ther. 193:64-72 (1975).